Genetic alterations in children and adolescents with acute myeloid leukaemia

Clinical and Translational Oncology

Volumn 12, Issue 9, 2010, Pages 590-596

  Verdeguer, Amparo ^a  

^a NONE

Author keywords

Cytogenetics; Leukemogenesis; Molecular rearrangements; Pediatric acute myeloid leukemia; Prognostic factors

Indexed keywords

ARSENIC; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORE BINDING FACTOR; ECOTROPIC VIRUS INTEGRATION 1 PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IMATINIB; K RAS PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MYOSIN HEAVY CHAIN; NUCLEOPHOSMIN; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN CBF BETA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN MKL1; PROTEIN N RAS; PROTEIN RBM15; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RNA BINDING PROTEIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE PROGRANULOCYTIC LEUKEMIA; ADOLESCENT; CANCER INCIDENCE; CANCER SURVIVAL; CHILD; CHILD HEALTH; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; MONOSOMY 7; PROGNOSIS; REVIEW; RISK FACTOR; TRISOMY 21; TRISOMY 8;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, 1-3; CHROMOSOMES, HUMAN, 13-15; CHROMOSOMES, HUMAN, 16-18; CHROMOSOMES, HUMAN, 21-22 AND Y; CHROMOSOMES, HUMAN, 6-12 AND X; CYTOGENETIC ANALYSIS; GENE EXPRESSION; HUMANS; INFANT; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS;

EID: 77958188757     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0563-z     Document Type: Review

References (68)

1. S.C. Raimondi M.N. Chang Y. Ravindranath, et al. 1999 Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG Blood 94 3707 3716 1:CAS:528:DyaK1MXnslykt7c%3D 10572083
2. H. Lapillonne L. Llopis A. Auvrignon, et al. 2010 Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia Leukemia 24 205 209 1:STN:280:DC%2BC3c%2FhvFyjsQ%3D%3D 10.1038/leu.2009.172 19759559
3. A. Dash D.G. Gilliland 2001 Molecular genetics of acute myeloid leukaemia Best Pract Res Clin Haematol 14 49 64 1:CAS:528:DC%2BD38XhvFagsw%3D%3D 10.1053/beha.2000.0115 11355923 (Pubitemid 32372401)
4. D.G. Gilliland J.D. Griffin 2002 The roles of FLT3 in hematopoiesis and leukemia Blood 100 1532 1542 1:CAS:528:DC%2BD38XmslyhsLc%3D 10.1182/blood-2002- 02-0492 12176867 (Pubitemid 34925124)
5. J.W. Vardiman J. Thiele D.A. Arber, et al. 2009 The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 937 951 1:CAS:528: DC%2BD1MXps1eit70%3D 10.1182/blood-2009-03-209262 19357394
6. C.J. Harrison R.K. Hills A.V. Moorman, et al. 2010 Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12 J Clin Oncol 28 2674 2681 10.1200/JCO.2009.24. 8997 20439644
7. U. Creutzig M. Zimmermann J. Ritter, et al. 2005 Treatment strategy and long term results in pediatric patients treated in four consecutive AML-BFM trials Leukemia 19 2030 2042 1:CAS:528:DC%2BD2MXht1ems7jI 10.1038/sj.leu.2403920 16304570 (Pubitemid 41741595)
8. N. Entz-Werle S. Suciu J. van der Werff ten Bosch, et al. 2005 Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report Leukemia 19 2072 2081 1:CAS:528:DC%2BD2MXht1ems7jE 10.1038/sj.leu.2403932 16136166 (Pubitemid 41741599)
9. B.J. Lange F.O. Smith J. Feusner, et al. 2008 Outcomes in CCG-2961, a Children's Oncology Group Phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group Blood 111 1044 1053 1:CAS:528:DC%2BD1cXhvFejsb4%3D 10.1182/blood-2007-04-084293 18000167 (Pubitemid 351213382)
10. Y. Ravindranath M. Chang C.P. Steuber, et al. 2005 Pediatric Oncology Group (POG) studies of acute myeloid leukaemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000 Leukemia 19 2101 2116 1:CAS:528:DC%2BD2MXht1ems7jL 10.1038/sj.leu.2403927 16136167 (Pubitemid 41741602)
11. D.R. Betts R.A. Ammann A. Hirt, et al. 2007 The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG) Eur J Haematol 78 468 476 10.1111/j.1600-0609.2007.00854.x 17419750 (Pubitemid 46753600)
12. E. Forestier S. Heim E. Blennow, et al. 2003 Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001 Br J Haematol 121 566 577 10.1046/j.1365-2141.2003.04349.x 12752097 (Pubitemid 36645377)
13. K. Mrózek N.A. Heerema C.D. Bloomfield 2004 Cytogenetics in acute leukemia Blood Rev 18 115 136 10.1016/S0268-960X(03)00040-7 15010150 (Pubitemid 38380667)
14. E. Forestier K. Schmiegelow 2006 Nordic Society of Paediatric Haematology and Oncology NOPHO. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations J Pediatr Hematol Oncol 28 486 495 1:CAS:528:DC%2BD28XpslGkt7c%3D 10.1097/01.mph.0000212972.90877.28 16912588 (Pubitemid 44257994)
15. C.D. Bloomfield A. Goldman D. Hassfeld, et al. 1984 Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia Cancer Genet Cytogenet 11 332 350 1:STN:280:DyaL2c7ls1ajsw%3D%3D 6704938 (Pubitemid 13193895)
16. T. Haferlach W. Kern C. Schoch, et al. 2004 A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group Haematologica 89 408 418 15075074 (Pubitemid 38798545)
17. J.C. Byrd K. Mrozek R.K. Dodge, et al. 2002 Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 4325 4336 1:CAS:528:DC%2BD38XpsFCqs7o%3D 10.1182/blood-2002-03-0772 12393746 (Pubitemid 35429670)
18. M.L. Slovak K.J. Kopecky P.A. Cassileth, et al. 2000 Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 4075 4083 1:CAS:528:DC%2BD3cXosl2hsbo%3D 11110676
19. Grimwade D, Hills RK (2009) Independent prognostic factors for AML outcome. Haematology Am Soc Hematol Educ Program 385-395
20. G.J.L. Kaspers C.N. Zwaan 2007 Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica 92 1519 1532 10.3324/haematol.11203 18024401 (Pubitemid 350144128)
21. F.R. Appelbaum H. Gundacker D.R. Head, et al. 2006 Age and acute myeloid leukaemia Blood 107 3481 3485 1:CAS:528:DC%2BD28Xkt1GitL8%3D 10.1182/blood-2005-09-3724 16455952
22. S. Tosi S. Tosi J. Harbott, et al. 2000 t(7;12) (q36;p13), a new recurrent translocation involving ETV6 in infant leukemia Genes Chromosomes Cancer 29 325 332 1:CAS:528:DC%2BD3cXot1Wjt7w%3D 10.1002/1098-2264(2000)9999: 9999<::AID-GCC1039>3.0.CO;2-9 11066076
23. R.M. Slater E. von Drunen W.G. Kroes, et al. 2001 t(7;12)(q36;p13) and t(7;12)(q32;p13): Translocations involving ETV6 in children 18 months of age or younger with myeloid disorders Leukemia 15 915 920 1:CAS:528: DC%2BD3MXkvVOit7o%3D 10.1038/sj.leu.2402121 11417477 (Pubitemid 32529891)
24. K.N. Manola 2009 Cytogenetics of pediatric acute myeloid leukemia Eur J Haematol 83 391 405 1:CAS:528:DC%2BD1MXhsVOgs7%2FJ 10.1111/j.1600-0609.2009. 01308.x 19563518
25. C. von Neuhoff D. Reinhardt A. Sander, et al. 2010 Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98 J Clin Oncol 28 2682 2689 10.1200/JCO.2009.25.6321
26. J.E. Rubnitz S.C. Raimondi A.R. Halbert, et al. 2002 Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience Leukemia 16 2072 2077 1:STN:280:DC%2BD38vpsFKqsw%3D%3D 10.1038/sj.leu.2402633 12357359 (Pubitemid 35203450)
27. T.A. Alonzo R.J. Wells W.G. Woods, et al. 2005 Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era Leukmia 19 965 970 1:STN:280:DC%2BD2M3mvFGgsg%3D%3D 10.1038/sj.leu.2403763 (Pubitemid 40862006)
28. S.O. Lie J. Abrahamsson N. Clausen, et al. 2005 Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Nordic Society of Pediatric Hematology and Oncology (NOPHO): AML Study Group Leukemia 19 2090 2100 1:CAS:528:DC%2BD2MXht1ems7nL 10.1038/sj.leu.2403962 16304571 (Pubitemid 41741601)
29. J.E. Rubnitz S.C. Raimondi X. Tong, et al. 2002 Favorable impact of the t(9;11) in childhood acute myeloid leukemia J Clin Oncol 20 2302 2309 1:CAS:528:DC%2BD38XktVKrs70%3D 10.1200/JCO.2002.08.400 11981001 (Pubitemid 34441657)
30. B.V. Balgobind S.C. Raimondi J. Harbott, et al. 2009 Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study Blood 114 2489 2496 1:CAS:528: DC%2BD1MXht1Wktr3O 10.1182/blood-2009-04-215152 19528532
31. S. Lugthard E. van Drunen Y. van Norden, et al. 2008 High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated Blood 111 4329 4337 10.1182/blood-2007-10-119230
32. B.V. Balgobind S. Lugthart I.H. Hollink, et al. 2010 EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia Leukemia 24 942 949 1:CAS:528:DC%2BC3cXlvVOit78%3D 10.1038/leu.2010.47 20357826
33. S. Meyer W.D. Fergusson A.D. Whetton, et al. 2007 Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemiaderived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption Genes Chromosomes Cancer 46 359 372 1:CAS:528:DC%2BD2sXjtlGmt7s%3D 10.1002/gcc.20417 17243162 (Pubitemid 46411327)
34. I. Haltrich I. Haltrich M. Kost-Alimova, et al. 2006 Multipoint interphase FISH analysis of chromosome 3 abnormalities in 28 childhood AML patients Eur J Haematol 76 124 133 1:CAS:528:DC%2BD28XisFWkurs%3D 10.1111/j.1600-0609.2005.00576.x 16405433
35. N. Dastugue M. Lafage-Pochitaloff M.P. Pages, et al. 2002 Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): A study of the Groupe Francais de Cytogenetique Hematologique (GFCH) Blood 100 618 626 1:CAS:528:DC%2BD38XlsVWgtLY%3D 10.1182/blood-2001-12-0241 12091356 (Pubitemid 34761127)
36. J. Park M. Kim J. Lim, et al. 2009 Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): the incidence and correlation of a HLXB9 overexpression Cancer Genet Cytogenet 191 102 105 1:CAS:528:DC%2BD1MXmtVKiurw%3D 10.1016/j.cancergencyto.2009.02.007 19446746
37. R.M. Slater E. von Drunen W.G. Kroes, et al. 2001 t(7;12)(q36;p13) and t(7;12)(q32;p13)- translocations involving ETV6 in children 18 months of age or younger with myeloid disorders Leukemia 15 915 920 1:CAS:528: DC%2BD3MXkvVOit7o%3D 10.1038/sj.leu.2402121 11417477 (Pubitemid 32529891)
38. A.R. von Bergh E. van Drunen E.R. van Wering, et al. 2006 High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9 Genes Chromosomes Cancer 45 731 739 10.1002/gcc.20335
39. H.M. Simmons L. Oseth P. Nguyen, et al. 2002 Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML Leukemia 16 2408 2416 1:CAS:528:DC%2BD38XovFKku7g%3D 10.1038/sj.leu.2402773 12454746 (Pubitemid 36054375)
40. H. Hasle T.A. Alonzo A. Auvringon, et al. 2007 Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: and in ternational retrospective study Blood 109 4641 4647 1:CAS:528:DC%2BD2sXmt1OgtL4%3D 10.1182/blood-2006-10-051342 17299091 (Pubitemid 46827753)
41. C. Owen M. Barnett J. Fitzgibbon 2008 Familial myelodysplasia and acute myeloid leukemia-a review Br J Haematol 140 123 132 1:CAS:528: DC%2BD1cXitVOnt7k%3D 10.1111/j.1365-2141.2007.06909.x 18173751 (Pubitemid 350265048)
42. A. Hama H. Yagasaki Y. Takahashi, et al. 2008 Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome Br J Haematol 140 552 561 10.1111/j.1365-2141.2007.06971.x 18275433 (Pubitemid 351230083)
43. U. Bacher T. Haferlach W. Kern, et al. 2007 A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukaemia Haematologica 92 744 752 1:CAS:528:DC%2BD2sXhtFGqu73P 10.3324/haematol.10869 17550846 (Pubitemid 350155299)
44. C.M. Zwaan S. Meshinchi J.P. Radich, et al. 2003 FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance Blood 102 2387 2394 1:CAS:528:DC%2BD3sXnslykt7c%3D 10.1182/blood-2002-12-3627 12816873 (Pubitemid 37193574)
45. S. Meshinchi T.A. Alonzo D.L. Stirewalt, et al. 2006 Clinical implications of FLT3 mutations in pediatric AML Blood 108 3654 3661 1:CAS:528:DC%2BD28Xht1Kgs77L 10.1182/blood-2006-03-009233 16912228 (Pubitemid 44864541)
46. S. Meshinchi D.L. Stirewalt T.A. Alonzo, et al. 2008 Structural and numerical variation of FLT3/ITD in pediatric AML Blood 111 4930 4933 1:CAS:528:DC%2BD1cXmtlaiurg%3D 10.1182/blood-2008-01-117770 18305215
47. A. Shimada T. Taki K. Tabuchi, et al. 2008 Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group Pediatr Blood Cancer 50 264 269 10.1002/pbc.21318 17763464
48. C. Thiede C. Steudel B. Mohr, et al. 2002 Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 4326 4335 1:CAS:528:DC%2BD38XksFGlu7o%3D 10.1182/blood.V99.12.4326 12036858 (Pubitemid 34627197)
49. B. Falini C. Mecucci E. Tiacci, et al. 2005 Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 254 266 1:CAS:528:DC%2BD2MXmslShug%3D%3D 10.1056/NEJMoa041974 15659725 (Pubitemid 40110814)
50. C. Thiede S. Koch E. Creutzig, et al. 2006 Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood 107 4011 4020 1:CAS:528:DC%2BD28XkvFWhu7c%3D 10.1182/blood-2005-08- 3167 16455956 (Pubitemid 43726809)
51. P. Brown E. McIntyre R. Rau, et al. 2007 The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood 110 979 985 1:CAS:528:DC%2BD2sXos1CqsbY%3D 10.1182/blood-2007-02-076604 17440048 (Pubitemid 47267437)
52. I.H. Hollink C.M. Zwaan M. Zimmermann, et al. 2009 Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML Leukemia 23 262 270 1:CAS:528: DC%2BD1MXhs1Omu7s%3D 10.1038/leu.2008.313 19020547
53. R.G. Verhaak C.S. Goudswaard W. van Putten, et al. 2005 Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood 106 3747 3754 1:CAS:528: DC%2BD2MXht12ksbnM 10.1182/blood-2005-05-2168 16109776 (Pubitemid 41739008)
54. C. Preudhomme C. Sagot N. Boissel, et al. 2002 Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia:a study from the Acute Leukemia French Association (ALFA) Blood 100 2717 2723 1:CAS:528:DC%2BD38XotVGhsLg%3D 10.1182/blood-2002-03-0990 12351377
55. B.J. Wouters B. Lowenberg C.A.J. Erpelinck-Verschueren, et al. 2009 Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with favorable outcome Blood 113 3088 3091 1:CAS:528:DC%2BD1MXktFWnt74%3D 10.1182/blood-2008-09-179895 19171880
56. P.A. Ho T.A. Alonzo R.B. Gerbing, et al. 2009 Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group Blood 113 6558 6566 1:CAS:528:DC%2BD1MXotlWrurc%3D 10.1182/blood-2008-10-184747 19304957
57. S. Schnittger T.M. Kohl T. Haferlach, et al. 2006 KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 107 1791 1799 1:CAS:528:DC%2BD28XitFChsLY%3D 10.1182/blood-2005- 04-1466 16254134 (Pubitemid 43289355)
58. U. Bacher T. Haferlach W. Kern, et al. 2007 A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukaemia Haematologica 92 744 752 1:CAS:528:DC%2BD2sXhtFGqu73P 10.3324/haematol.10869 17550846 (Pubitemid 350155299)
59. B.F. Goemans C.M. Zwaan M. Miller, et al. 2005 Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia Leukemia 19 1536 1542 1:CAS:528:DC%2BD2MXovVOjurY%3D 10.1038/sj.leu.2403870 16015387 (Pubitemid 43090396)
60. A. Shimada T. Taki K. Tabuchi, et al. 2006 KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group Blood 107 1806 1809 1:CAS:528:DC%2BD28XitFyht7c%3D 10.1182/blood-2005-08-3408 16291592 (Pubitemid 43289357)
61. U. Keilholz H.D. Menssen A. Gaiger, et al. 2005 Wilms' tumour gene 1 (WT1) in human neoplasia Leukemia 19 1318 1323 1:CAS:528:DC%2BD2MXmtlSjsrk%3D 10.1038/sj.leu.2403817 15920488 (Pubitemid 41136321)
62. V.I. Gaidzik R.F. Schlenk S. Moschny, et al. 2009 Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group Blood 113 4505 4511 1:CAS:528: DC%2BD1MXnvVyqtLc%3D 10.1182/blood-2008-10-183392 19221039
63. H. Lapillonne A. Renneville A. Auvrignon, et al. 2006 High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia J Clin Oncol 24 1507 1515 1:CAS:528:DC%2BD28XjvFyktr8%3D 10.1200/JCO.2005.03.5303 16575000 (Pubitemid 46638771)
64. L. Boublikova M. Kalinova J. Ryan, et al. 2006 Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring Leukemia 20 254 263 1:CAS:528:DC%2BD28Xmsl2qtw%3D%3D 10.1038/sj.leu.2404047 16341043 (Pubitemid 43148663)
65. P. Paschka G. Marcucci A.S. Ruppert, et al. 2008 Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study J Clin Oncol 26 4595 4602 1:CAS:528:DC%2BD1cXht1KqtLfJ 10.1200/JCO.2007.15.2058 18559874
66. I.H. Hollink M.M. van den Heuvel-Eibrink M. Zimmermann, et al. 2009 Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia Blood 113 5951 5960 1:CAS:528:DC%2BD1MXnsVSktrk%3D 10.1182/blood-2008- 09-177949 19171881
67. S.P. Whitman A.S. Ruppert G. Marcucci, et al. 2007 Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study Blood 109 5164 5167 1:CAS:528:DC%2BD2sXmslOrsr0%3D 10.1182/blood-2007-01-069831 17341662 (Pubitemid 46890532)
68. M. Tallman 2008 Existing and emerging therapeutic options for the treatment of acute myeloid leukemia Clinical advances in Hematology & Oncology 6 Suppl18 3 10